Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial
Aim. Evaluation of the efficacy and safety of the drug Aterixen® (XC221GI, 1-[2-(1-methylimidazole-4-yl)-ethyl]perhydroazine-2,6-dione), in the treatment of uncomplicated forms of influenza and other ARVI in adults. Materials and methods. The phase III clinical trial enrolled 260 people aged 18–6...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2023-12-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/626343/142220 |
| _version_ | 1797261501043572736 |
|---|---|
| author | Andrey G. Malyavin Madina I. Bagaeva Oleg V. Kalyuzhin |
| author_facet | Andrey G. Malyavin Madina I. Bagaeva Oleg V. Kalyuzhin |
| author_sort | Andrey G. Malyavin |
| collection | DOAJ |
| description | Aim. Evaluation of the efficacy and safety of the drug Aterixen® (XC221GI, 1-[2-(1-methylimidazole-4-yl)-ethyl]perhydroazine-2,6-dione), in the treatment of uncomplicated forms of influenza and other ARVI in adults.
Materials and methods. The phase III clinical trial enrolled 260 people aged 18–65 years with mild and moderate forms of influenza or other ARVI. Patients were randomly assigned to two groups: in group 1 (n=130), patients were prescribed the drug Aterixen® in tablets of 100 mg 2 times a day for 5 days; in group 2 (n=130) – a placebo corresponding to the drug, in the same regimen. The primary endpoint of the efficacy assessment was the time in hours from the first administration of the drug to clinical improvement. The main efficacy analysis was performed in a population of patients with PCR-confirmed influenza or ARVI who completed the study according to the protocol (per protocol infected). Additionally, efficacy was evaluated in ITT and PP populations, including patients with both identified and undetected pathogen. The population for safety analysis included all patients, without exception, who were exposed to at least one exposure to the study drug or placebo.
Results. A statistically significant superiority of the drug Aterixen® over placebo in primary endpoint was revealed in both the main and additional analysis in all studied populations: clinical improvement in the group of the studied drug occurred 24 hours faster compared with the placebo group. The evaluation of the effectiveness of secondary endpoints confirmed the superiority of the drug Aterixen® over placebo in terms of relief of catarrhal symptoms and symptoms of intoxication. A favorable safety profile of the drug has been demonstrated.
Conclusion. The drug has demonstrated a favorable safety profile for use in outpatient practice. Aterixen® is an effective and safe treatment for influenza and other ARVI in adults. |
| first_indexed | 2024-04-24T23:42:13Z |
| format | Article |
| id | doaj.art-573070f735b64e71baae090ad1b1c940 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-04-24T23:42:13Z |
| publishDate | 2023-12-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-573070f735b64e71baae090ad1b1c9402024-03-15T10:06:07Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422023-12-0195121165117110.26442/00403660.2023.12.20255478421Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trialAndrey G. Malyavin0https://orcid.org/0000-0002-6128-5914Madina I. Bagaeva1https://orcid.org/0000-0002-4577-1832Oleg V. Kalyuzhin2https://orcid.org/0000-0003-3628-2436Russian University of MedicineValenta Pharm Pharmaceutical Company JSCSechenov First Moscow State Medical University (Sechenov University)Aim. Evaluation of the efficacy and safety of the drug Aterixen® (XC221GI, 1-[2-(1-methylimidazole-4-yl)-ethyl]perhydroazine-2,6-dione), in the treatment of uncomplicated forms of influenza and other ARVI in adults. Materials and methods. The phase III clinical trial enrolled 260 people aged 18–65 years with mild and moderate forms of influenza or other ARVI. Patients were randomly assigned to two groups: in group 1 (n=130), patients were prescribed the drug Aterixen® in tablets of 100 mg 2 times a day for 5 days; in group 2 (n=130) – a placebo corresponding to the drug, in the same regimen. The primary endpoint of the efficacy assessment was the time in hours from the first administration of the drug to clinical improvement. The main efficacy analysis was performed in a population of patients with PCR-confirmed influenza or ARVI who completed the study according to the protocol (per protocol infected). Additionally, efficacy was evaluated in ITT and PP populations, including patients with both identified and undetected pathogen. The population for safety analysis included all patients, without exception, who were exposed to at least one exposure to the study drug or placebo. Results. A statistically significant superiority of the drug Aterixen® over placebo in primary endpoint was revealed in both the main and additional analysis in all studied populations: clinical improvement in the group of the studied drug occurred 24 hours faster compared with the placebo group. The evaluation of the effectiveness of secondary endpoints confirmed the superiority of the drug Aterixen® over placebo in terms of relief of catarrhal symptoms and symptoms of intoxication. A favorable safety profile of the drug has been demonstrated. Conclusion. The drug has demonstrated a favorable safety profile for use in outpatient practice. Aterixen® is an effective and safe treatment for influenza and other ARVI in adults.https://ter-arkhiv.ru/0040-3660/article/viewFile/626343/142220arviacute respiratory infectionsinfluenzarespiratory virusesaterixen®хс221gi |
| spellingShingle | Andrey G. Malyavin Madina I. Bagaeva Oleg V. Kalyuzhin Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial Терапевтический архив arvi acute respiratory infections influenza respiratory viruses aterixen® хс221gi |
| title | Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial |
| title_full | Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial |
| title_fullStr | Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial |
| title_full_unstemmed | Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial |
| title_short | Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial |
| title_sort | application of hs221gi in treatment of influenza and arvi in adults a new approach managing virus induced inflammation results of a double blind randomized placebo controlled multicenter clinical trial |
| topic | arvi acute respiratory infections influenza respiratory viruses aterixen® хс221gi |
| url | https://ter-arkhiv.ru/0040-3660/article/viewFile/626343/142220 |
| work_keys_str_mv | AT andreygmalyavin applicationofhs221giintreatmentofinfluenzaandarviinadultsanewapproachmanagingvirusinducedinflammationresultsofadoubleblindrandomizedplacebocontrolledmulticenterclinicaltrial AT madinaibagaeva applicationofhs221giintreatmentofinfluenzaandarviinadultsanewapproachmanagingvirusinducedinflammationresultsofadoubleblindrandomizedplacebocontrolledmulticenterclinicaltrial AT olegvkalyuzhin applicationofhs221giintreatmentofinfluenzaandarviinadultsanewapproachmanagingvirusinducedinflammationresultsofadoubleblindrandomizedplacebocontrolledmulticenterclinicaltrial |